Giacomo Emanuele Maria Rizzo

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Ilaria Tarantino

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

Mario Traina

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

Dario Ligresti

Istituti di Ricovero e Cura a Carattere Scientifico

Lucio Carrozza

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

Gabriele Rancatore

University of Palermo

Giuseppe Cabibbo

University of Palermo

Ciro Celsa

University of Palermo

Calogero Cammà

University of Palermo

Marco Enea

University of Palermo

Carlo Fabbri

Azienda-Unita' Sanitaria Locale Di Cesena

Cooperative Institutions

Istituti di Ricovero e Cura a Carattere Scientifico

121

University of Palermo

104

University of Bologna

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

Collaborative Group (United States)

Policlinico S.Orsola-Malpighi

University of Padua

Azienda USL di Bologna

Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo

University of Palermo

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

The 1st i-EUS consensus on the management of pancreatic fluid collections – Part 2

Digestive and Liver Disease (2024)

Gabriele Capurso Chiara Coluccio Giacomo Emanuele Maria Rizzo Stefano Francesco Crinò Alessandro Cucchetti

10.1016/j.dld.2024.06.004

Cite

Citations (0)

Management of malignant gastric outlet obstruction (mGOO) due to pancreatic cancer in the era of EUS-gastroenterostomy: an international practice survey and case vignette study

Pancreatology (2023)

Charles de Ponthaud Bahadır Osman Bozkirli Gabriele Capurso Sébastien Gaujoux Giacomo Emanuele Maria Rizzo

Gastroenterostomy

Vignette

Gastric Outlet Obstruction

10.1016/j.pan.2023.06.634

Cite

Citations (0)

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

Gut (2021)

Víctor Sapena Marco Enea Ferrán Torres Ciro Celsa José Ríos

Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration. Design We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson. Results Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I 2 =74.6%) and 5.7 (2.5 to 15.3, I 2 =54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p<0.001), performance status (2 vs 0, RR=4.35, 95% CI 1.54 to 11.11; 2 vs 1, RR=3.7, 95% CI 1.3 to 11.11; p=0.01) and tumour burden pre-HCC treatment (multifocal vs solitary nodule, RR=1.75, 95% CI 1.25 to 2.43; p<0.001). No significant difference was observed in RR between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (RR=0.64, 95% CI 0.37 to 1.1; p=0.1). Conclusion Effects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.

Antiviral Therapy

10.1136/gutjnl-2020-323663

Cite

Citations (85)

Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis

Cancers (2020)

Giuseppe Cabibbo Ciro Celsa Marco Enea Salvatore Battaglia Giacomo Emanuele Maria Rizzo

Background: An optimal sequential systemic therapy for advanced hepatocellular carcinoma (HCC) has not been discovered. We developed a decision model based on available clinical trials to identify an optimal risk/benefit strategy for sequences of novel systemic agents. Methods: A Markov model was built to simulate overall survival (OS) among patients with advanced HCC. Three first-line (single-agent Sorafenib or Lenvatinib, and combination of Atezolizumab plus Bevacizumab) followed by five second-line treatments (Regorafenib, Cabozantinib, Ramucirumab, Nivolumab, Pembrolizumab) were compared in fifteen sequential strategies. The likelihood of transition between states (initial treatment, cancer progression, death) was derived from clinical trials. Life-year gained (LYG) was the main outcome. Rates of severe adverse events (SAEs) (≥grade 3) were calculated. The innovative measure, called incremental safety-effectiveness ratio (ISER), of the two best sequential treatments was calculated as the difference in probability of SAEs divided by LYG. Results: Lenvatinib followed by Nivolumab (median OS, 27 months) was the most effective sequence, producing a LYG of 0.75, while Atezolizumab plus Bevacizumab followed by Nivolumab was the safest sequence (SAEs 40%). Accordingly, the net health benefit assessed by ISER favored Lenvatinib followed by Nivolumab, compared to Atezolizumab plus Bevacizumab, followed by Nivolumab in 52% of cases. Conclusion: Further sequential clinical trials or large-scale real-world studies may prove useful to evaluate the net health benefit of the best sequential treatment for advanced HCC.

Lenvatinib

Atezolizumab

Ramucirumab

Regorafenib

Cabozantinib

10.3390/cancers12082132

Cite

Citations (22)

Navigating the Labyrinth: When the “Mesenterium Commune” Turns Colonoscopy into an Endoscopic Rollercoaster

Diagnostics (2024)

Giacomo Emanuele Maria Rizzo Silvia Ferriolo Lucio Carrozza Gabriele Rancatore Mario Traina

These images involved the case of a 51-year-old woman who had a history of chronic abdominal pain, iron deficiency, and diarrhoea but no blood or mucus in her stool. She had never undergone major abdominal surgery, and her past medical evaluation diagnosed her with celiac disease, leading to the adoption of a gluten-free diet alleviating most of her gastrointestinal symptoms. However, years later, her abdominal pain returned, so she underwent an abdominal ultrasound, revealing non-specific bowel loop dilation, and a weakly positive faecal occult blood test led to a colonoscopy. Despite many efforts to advance the scope beyond the transverse colon, colonoscopy was arduous and not complete, even after several changes in decubitus and abdominal compressions. Therefore, a virtual colonoscopy was conducted, revealing no intraluminal masses, but the entire colon was located on the left side of the abdomen. Indeed, the results showed sigma and that most of the colon was curled up in the small pelvis. This rare anatomical variant, known as “Mesenterium commune” (MC), is a type of gut malrotation that develops in childhood due to a lack of omphalomesenteric loop rotation during the embryonic period. This condition can lead to episodes of intestinal obstruction, potentially resulting in an acute abdomen and leading to surgical correction. Symptoms include chronic recurring abdominal pain, nausea, vomiting, and occasionally bloody stools. Few cases of this extremely rare condition have been reported in the literature so far.

Intestinal Malrotation

Transverse colon

Abdominal distension

10.3390/diagnostics14111072

Cite

Citations (0)

Long-term outcomes of patients with chronic HBsAg positive/HBe-negative infection: differences and transition between inactive carriers and low viremic carriers

Journal of Hepatology (2023)

Giacomo Emanuele Maria Rizzo Gabriele Rancatore Pietro Graceffa Giuseppe Falco F. Bronte

10.1016/s0168-8278(23)03228-2

Cite

Citations (0)

Successful multidisciplinary urgent management of life-threatening intraprocedural bleeding after EUS-guided fine-needle biopsy of a pulmonary mass

VideoGIE (2023)

Giacomo Emanuele Maria Rizzo Mario Traina Lucio Carrozza Dario Ligresti Alessandro Bertani

Video 1Multidisciplinary management of an intraprocedural endobronchial bleeding after EUS-guided transesophageal FNB of a pulmonary mass.

10.1016/j.vgie.2023.08.002

Cite

Citations (0)

Management of malignant Gastric Outlet Obstruction (mGOO) due to pancreatic cancer in the era of EUS-Gastrojejunostomy: an international practice survey and case vignette study by Pancreas 2000 from the European Pancreatic Club

Surgical Endoscopy (2024)

Charles de Ponthaud Bahadır Osman Bozkirli Giacomo Emanuele Maria Rizzo Stuart Robinson Filipe Vilas‐Boas

Specialty

Gastric Outlet Obstruction

Vignette

10.1007/s00464-024-10803-0

Cite

Citations (6)

Model for end stage liver disease for prediction of mortality in people with cirrhosis

Cochrane library (2021)

Gennaro D’Amico Giovanni Perricone Alberto Morabito F Latteri Daniela Filì

Liver disease

10.1002/14651858.cd013849

Cite

Citations (0)

SARS‐CoV‐2 infection in patients with a normal or abnormal liver

Journal of Viral Hepatitis (2020)

Giuseppe Cabibbo Giacomo Emanuele Maria Rizzo Caterina Stornello Antonio Craxı̀

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel coronavirus causing coronavirus disease 19 (COVID-19), with an estimated 22 million people infected worldwide so far although involving primarily the respiratory tract, has a remarkable tropism for the liver and the biliary tract. Patients with SARS-CoV-2 infection and no antecedent liver disease may display evidence of cytolytic liver damage, proportional to the severity of COVID-19 but rarely of clinical significance. The mechanism of hepatocellular injury is unclear and possibly multifactorial. The clinical impact of SARS-CoV-2 infection in patients with underlying chronic liver disease, a cohort whose global size is difficult to estimate, has been assessed appropriately only recently and data are still evolving. Patients with cirrhosis are at higher risk of developing severe COVID-19 and worse liver-related outcomes as compared to those with non-cirrhotic liver disease. OLT patients have an intermediate risk. Specific interventions in order to reduce the risk of transmission of infection among this high-risk population have been outlined by international societies, together with recommendations for modified treatment and follow-up regimens during the COVID-19 pandemic. When a vaccine against SARS-CoV-2 becomes available, patients with fibrotic liver disease and those with OLT should be considered as prime targets for prophylaxis of COVID-19, as all other highly susceptible subjects.

Liver disease

Coronavirus

10.1111/jvh.13440

Cite

Citations (40)